GALDERMA Science in the service of dermatologists Dedicated exclusively to dermatology, Galderma’s ambition is to be recognised as the most competent and innovative company in its field. With innovation and research at the heart of its strategy, Galderma is bringing scientific progress to patients and doctors and fostering advances in the field of dermatology throughout the world. <strong>2008</strong> REVIEW Galderma experienced an exceptional year with a like-for-like sales growth of +17.1%. The company continued to gain market share in its traditional markets particularly in North America, where sales have increased by +18.5%. The main growth drivers, Differin ® and Epiduo (acne), Rozex ® /Metro ® and Oracea ® (rosacea), Clobex ® (psoriasis), Dysport ® (frown lines) and Cetaphil ® (therapeutic skincare line), all contributed to the significant increase in Galderma’s market share. 2009 OutLOOK COnSOLIDAtED SALES BY GEOGRAPHIC zOnE (1) E millions —DIFFERIN ® Reference product for acne, the first topical retinoid approved in Japan. Galderma will continue its worldwide roll-out of Epiduo , a new acne treatment, in the United States in particular, where it was approved at the end of <strong>2008</strong>. Vectical ® , for the treatment of psoriasis, will enhance Galderma’s American subsidiary’s product range. Several strategic products will be launched in Europe: Oracea ® to treat rosacea, Clobex ® Shampoo, acknowledged as a reference treatment for psoriasis, and Azzalure ® to reduce frown lines. —EPIDUO A unique combination treatment for acne discovered and developed by Galderma. 2007 <strong>2008</strong> % of <strong>2008</strong> sales —ORAcEA ® The first oral treatment for rosacea authorized in the United States. Growth <strong>2008</strong>/2007 Like-for-like Published figures Western Europe 187.2 196.6 23.0% +7.3% +5.0% North America 409.8 492.0 57.6% +18.5% +20.1% Rest of the World 138.0 165.2 19.4% +26.3% +19.7% TOTAL 735.0 853.8 100% +17.1% +16.2% (1) 100% of Galderma’s sales. Businesses — Dermatology Through the acquisition of CollaGenex in the United States, Galderma has enhanced its product portfolio with Oracea ® , the first oral treatment for rosacea authorized by the FDA (Food and Drug Administration), as well as two topical products which are under development. In Japan, the second largest dermatology market in the world, the launch of Differin ® represents an important landmark in Galderma’s history. This reference product for acne, the result of Galderma’s own research, is the first topical retinoid approved in Japan. Epiduo , a unique combination treatment for acne, which was also discovered and developed by Galderma, is highly-recognised for its therapeutic innovation and is successfully gaining ground in Latin America and Europe. In order to meet the evolving needs of doctors and patients, Galderma is entering the corrective and aesthetic dermatology segment with the marketing of Dysport ® in Latin America, a botulinum toxin type A, for the treatment of frown lines. The European launch is planned for 2009. The company continues to develop partnerships with health professionals and the scientific community. Intense R&D activity has resulted in significant progress on several major projects, some fifty patent filings to protect innovation and numerous product registrations. Product launches and the increase in production of strategic brands internally mean that the plants have reached unprecedented activity levels. In addition, the French, Canadian and Brazilian sites all received or renewed certification in <strong>2008</strong>. Galderma is thus stepping up its initiatives to improve safety and protect the environment. Galderma continues to pursue its commitment: to develop ever more innovative, diverse and complementary medical solutions to foster advances in the field of dermatology throughout the world. 71
72 North America €3,739 million of consolidated sales (1) 18.2% market share (2) 22.9% of group cosmetics sales (1) Consolidated cosmetics sales. (2) Excluding soaps, toothpaste and razors. Provisional <strong>2008</strong> estimates with YSL Beauté over a full year. Source: L’Oréal estimates. INTERNATIONAL Latin America €1,151 million of consolidated sales (1) 12.1% market share (2) 7.0% of group cosmetics sales SEIZING THE POTENTIAL IN ALL MARKETS
- Page 1 and 2:
2008 Annual Report
- Page 4 and 5:
The L’Oréal adventure Inventing
- Page 6 and 7:
Deepening our values In 2008, L’O
- Page 8 and 9:
Operating profit proves resilient I
- Page 10 and 11:
Board of Directors COMPOSITION AT D
- Page 12 and 13:
8 Jean-Philippe Blanpain Managing D
- Page 14 and 15:
of inspiration and creativity, of b
- Page 16 and 17:
1982 Patented by L’Oréal Researc
- Page 18 and 19:
To be sustainable, L’Oréal’s g
- Page 20 and 21:
Product meeting: developing and sha
- Page 22 and 23:
The Strategy and Implementation Com
- Page 24 and 25: Sustainable Development — Philant
- Page 26 and 27: Water L’Oréal is striving to ach
- Page 28 and 29: 2008 Consolidated sales of the cosm
- Page 30 and 31: 2008 Balance sheet and cash flows b
- Page 32 and 33: 2003 2004 14,029 14,534 1,870 2,063
- Page 34 and 35: The L’Oréal share key figures (a
- Page 36 and 37: Skincare: number 1 category in the
- Page 38 and 39: In 2020… … 1 billion young seni
- Page 40 and 41: The vocation of the group’s brand
- Page 42: Luxury Products The Luxury Products
- Page 45 and 46: 42 Businesses — Professional Prod
- Page 47 and 48: 44 Businesses — Professional Prod
- Page 50 and 51: Consumer PRODUCTS L’ORÉAL PARIS
- Page 52 and 53: Skincare records the highest growth
- Page 54 and 55: —GARNIER England. L’ORÉAL PARI
- Page 56 and 57: SOFtSHEEn·CARSOn So f TSheen·ca r
- Page 59 and 60: 56 Businesses — Luxury Products 2
- Page 61 and 62: 58 Businesses — Luxury Products
- Page 63 and 64: 60 Businesses — Luxury Products
- Page 65: 62 Cosmetics ACTIVE VICHY LA ROCHE-
- Page 68 and 69: Another year of double-digit growth
- Page 70 and 71: —LA ROcHE-POSAy China. —SKINcEU
- Page 72 and 73: Opening of the first The Body Shop
- Page 76 and 77: Western Europe €7,382 million of
- Page 78 and 79: Advice is vital in mass-market dist
- Page 80 and 81: L’Or é a L Pr O f e s s i O n n
- Page 82 and 83: Ga r n i e r Nutritioniste Anti-puf
- Page 84 and 85: In Brazil, its second largest marke
- Page 86 and 87: With its full brand portfolio, L’
- Page 88 and 89: As nine out of ten South African wo
- Page 90 and 91: L’Oréal’s success is based on
- Page 92 and 93: esearchers, and thousands of head t
- Page 94 and 95: InVEntInG A CEntuRY OF BEAutY From
- Page 96 and 97: COmBInInG PACKAGInG InnOVAtIOn WItH
- Page 98 and 99: BuSInESS GAmES—A unIquE EXPERIEnC
- Page 100 and 101: Taking actions for diversity and eq
- Page 102 and 103: tAX The mission of the Tax departme
- Page 104 and 105: Published by the Administration and
Change language